Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 3/20 | 0.43 |
| ▸ | CHRNA4 | P43681 | 3/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17841557 | 0.94 | CHRNB2 (0.44) | CHRNB2CHRNA4NPC1RAB9A | |
| SCHEMBL17841473 | 0.89 | CHRNB2 (0.46) | CHRNB2CHRNA4NPC1RAB9A | |
| SCHEMBL19668758 | 0.88 | CHRNB2 (0.46) | CHRNB2CHRNA4NPC1RAB9A | |
| SCHEMBL1557490 | 0.84 | GGPS1 (0.49) | CHRNB2CHRNA4NPC1RAB9AMAPT | |
| SCHEMBL6253280 | 0.83 | CHRNB2 (0.43) | CHRNB2CHRNA4NPC1RAB9A | |
| SCHEMBL27880039 | 0.82 | GGPS1 (0.51) | CHRNB2CHRNA4MAPT | |
| SCHEMBL31393027 | 0.81 | CYP11B1 (0.45) | CHRNB2CHRNA4MAPT | |
| SCHEMBL7924171 | 0.81 | MAPT (0.47) | CHRNB2CHRNA4MAPTLMNACYP1A2 | |
| SCHEMBL21465056 | 0.80 | CHRNB2 (0.48) | CHRNB2CHRNA4NPC1RAB9ALMNA | |
| SCHEMBL1621537 | 0.79 | AKT1 (0.51) | CHRNB2CHRNA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080293684-A1 | Heterocyclic Acetophenone Potentiators of Metabotropic Glutamate Receptors | MERCK SHARP & DOHME CORP. | 2008-11-27 | — | — | US | disclosed |
| CN-1993326-A | Heterocyclic acetophenone potentiators of metabotropic glutamate receptors | MERCK & CO INC (US) | 2007-07-04 | — | — | CN | disclosed |
| EP-1773774-A2 | HETEROCYCLIC ACETOPHENONE POTENTIATORS OF METABOTROPIC GLUTAMATE RECEPTORS | Merck & Co., Inc. (US) | 2007-04-18 | — | — | EP | disclosed |
| WO-2006014918-A2 | HETEROCYCLIC ACETOPHENONE POTENTIATORS OF METABOTROPIC GLUTAMATE RECEPTORS | MERCK & CO., INC. (US) | 2006-02-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080293684-A1 | Heterocyclic Acetophenone Potentiators of Metabotropic Glutamate Receptors | GRM2, GRM1, GRIK2 | CHRNB2 141/4885CHRNA4 102/4885NPC1 2147/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.